Senior Manager, Business Development Global Evaluation

Novo Nordisk; Cambridge (MA); On-site; USD 180,000 - 240,000; Full time

Job summary

Novo Nordisk Cambridge is seeking a leader in Global Business Development to drive external partnerships, collaborations and acquisitions. The role focuses on identifying opportunities, conducting due diligence, and guiding negotiations from discovery to integration.

You will work with cross-functional teams across Denmark and the US, report to the Sr. Director, Global Evaluation, and engage with biotech firms, venture capitalists, and academic partners to advance strategic initiatives.

Responsibilities

• Contribute to scouting and report opportunities from networks, literature, patents, conferences
• Support in-depth evaluation and due diligence process
• Support the technical streams of the Business Development process from initial evaluation through due diligence
• Assist in preparing presentations to governance boards and building the value story for opportunities

Job description

About The Department

The Novo Nordisk Cambridge location is the headquarters for Global Business Development across all of our therapeutic and technology areas. We contribute to innovation in one of the world's largest life sciences ecosystems by participating in events and discussions with renowned and upcoming scientists looking for the next scientific breakthrough to bring transformative treatments to patients. We work with start-ups, established companies, venture capitalists, teaching hospitals, and academic institutions to support the development of innovation for mutual benefit, and to help patients in all of our current therapy areas. Through a variety of partnership models, we accelerate ideas from the lab and clinic to advance and expand our product portfolio and to improve outcomes for the patients we serve

About The Department

The Novo Nordisk Cambridge location is the headquarters for Global Business Development across all of our therapeutic and technology areas. We contribute to innovation in one of the world's largest life sciences ecosystems by participating in events and discussions with renowned and upcoming scientists looking for the next scientific breakthrough to bring transformative treatments to patients. We work with start-ups, established companies, venture capitalists, teaching hospitals, and academic institutions to support the development of innovation for mutual benefit, and to help patients in all of our current therapy areas. Through a variety of partnership models, we accelerate ideas from the lab and clinic to advance and expand our product portfolio and to improve outcomes for the patients we serve

The Position

Global Business Development is responsible for Novo Nordisk’s corporate business development activities related to establishing external partnerships, collaborations and acquisitions, as well as integration and alliance management. The Group Vice President (GVP) area consists of units covering business development from end-to-end with Search, Evaluation & Intelligence, BD and M&A Transactions, Integration and Alliance Management. Search, Evaluation & Intelligence (SE&I) is part of GBD and acts as the primary entry point for external drug and technology opportunities relevant to Novo Nordisk. SE&I conducts proactive scouting campaigns to identify relevant opportunities by targeting start-ups, biotechnology companies and venture capital firms, by means of partnering events, scientific conferences and relevant industry events. The search for novel therapeutics focuses on our core areas: diabetes, obesity, CVD, Liver, blood & endocrine disorders and Consumer Rx. Working cross-functionally, SE&I supports the assessment of such external opportunities all the way to due diligence and contractual negotiation. The role is a driver for change in executing Novo Nordisk's strategy and business development activities on a global scale and has the following responsibilities: Identification of novel pipeline assets and enabling technologies. Strategic overview of internal, as well as BD, pipeline assets. Evaluation of novel pipeline assets and enabling technologies. Independence: Moderate. Works independently on specific projects, requiring guidance and input from manager/senior team members for broader strategy or significant issues. Decision-making: Moderate. Responsible for making decisions within defined parameters, leading projects, but often seeks approval from the manager for larger decisions.

Relationships

The position is part of the global SE&I evaluation team with members located predominantly in Denmark and Cambridge, MA, US. Reports to the Sr. Director, Global Evaluation. The role will interact cross-functionally with stakeholders from the entire value chain while working in close collaboration with Novo Nordisk’s Business Development teams located in Denmark and Cambridge. This position will also leverage their networks and actively engage with external stakeholders including biotech companies, venture capital firms and large-cap pharma communities. The role has no direct or indirect reports.

Essential Functions

• Contribute to and support identification of novel pipeline assets and enabling technologies
• Contribute to scouting and report opportunities that may come across through professional networks or literature searches, databases or patent searches, conferences or other ways within relevant therapy areas, i.e. diabetes, obesity, CVD, Liver, rare blood/endocrine disorders and Consumer Rx
• Support in-depth evaluation and due diligence process
• Support the technical streams of the Business Development process from involvement in initial evaluation through due diligence processes
• Assist in preparing presentations of selected opportunities to relevant governance boards; and building the value story for our opportunities, as well as due diligence project management, to enable senior management decision-making